Overview

A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-03-04
Target enrollment:
Participant gender:
Summary
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - multiple ascending dose (MAD) phase, and Part C - Food Effect (FE) phase.
Phase:
Phase 1
Details
Lead Sponsor:
Xuanzhu Biopharmaceutical Co., Ltd.